Cleavable scFv-Transferrin Fusion for Selective BBB Antibody Transport
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods to deliver monoclonal antibodies across the BBB are inefficient and invasive, particularly disrupting the tight junctions to achieve selective delivery of antibodies in the CNS.
Innovation Solution
The use of a single-chain variable fragment (scFv) with Sequence No. 1 and Sequence No. 2, which is capable of delivering various antibodies across the BBB, using transferrin to achieve selective delivery of antibodies in the CNS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If monoclonal antibodies are administered systemically to treat CNS disorders, then the therapeutic coverage is broad and convenient, but the ability to cross the blood-brain barrier is insufficient
Solution Approach 1:
The patent uses a bispecific antibody structure where one arm binds to the transferrin receptor (TfR) on the BBB endothelial cells to facilitate transcytosis, while the other arm binds to the therapeutic target (amyloid-beta, tau, or alpha-synuclein) in the brain. This intermediary mechanism enables the antibody to cross the BBB effectively while maintaining therapeutic function.
Solution Approach 2:
The invention creates a composite antibody structure combining two specific binding functions in a single molecule. The bispecific antibody integrates TfR-binding capability with pathogen-target-binding capability, forming a composite therapeutic agent that simultaneously achieves BBB penetration and therapeutic efficacy.
2Productivity
If the blood-brain barrier is disrupted to allow antibody passage, then delivery efficiency improves, but selectivity is lost and harmful blood components can enter the brain
Solution Approach 1:
The bispecific antibody acts as a selective intermediary that exploits the natural TfR-mediated transcytosis pathway. This receptor-mediated mechanism maintains the selective barrier function of the BBB while facilitating controlled passage of the therapeutic antibody, preventing non-selective entry of harmful blood components.
Solution Approach 2:
The invention changes the molecular parameters of the antibody by creating a bispecific structure with altered binding properties. This enables the antibody to utilize specific receptor pathways for controlled transport across the BBB, maintaining selectivity while improving delivery efficiency.
3Reliability
If bisspecific antibodies are used to enhance BBB penetration, then the amount of antibody reaching the brain increases, but manufacturing complexity and cost increase significantly
Solution Approach 1:
The bispecific antibody structure is designed to be universally applicable to multiple CNS therapeutic targets (amyloid-beta, tau, alpha-synuclein) by maintaining one arm for TfR binding and the other arm for target binding. This multi-functional design streamlines development across different indications while achieving reliable BBB penetration.
4Reliability
If monoclonal antibodies are used to treat neurodegenerative disorders, then therapeutic efficacy is achieved, but brain exposure levels remain insufficient
Solution Approach 1:
The TfR-binding capability of the bispecific antibody serves as an intermediary mechanism to actively transport the therapeutic agent across the BBB, significantly increasing the quantity of antibody reaching the brain parenchyma compared to passive diffusion or systemic administration alone.
Solution Approach 2:
The composite bispecific antibody structure combines BBB-penetration functionality with high-affinity target binding, ensuring both sufficient brain exposure concentration and therapeutic efficacy against neurodegenerative pathology.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of a single-chain variable fragment (scFv) with a cleavable linker to connect the scFv with a cleavable linker to connect the scFv with transferrin protein.
Implementation Method 1
Macromolecules such as monoclonal antibodies ("mAbs") can utilize three types of vesicles to traverse brain endothelial cells: (i) clathrin-coated vesicles, (ii) caveolae domains generated from lipid rafts, and (iii) macropinocytotic vesicle. For transcytosis of large molecules, which primarily uses clathrin-coated vesicles, a receptor is required for uptake and trafficking across the brain endothelial cells. This process has been termed "receptor-mediated transcytosis" ("RMT").
Data Source
AI summary
Antibodies can treat neurodegenerative disorders (NDs) caused by misfolded proteins. Still, the blood-brain-barrier (BBB) resists their entry, a barrier that can be reduced by scFv instead of whole antibody and conjugating it with transferrin protein to induce transcytosis. While the scFv binds variable heavy and light chains with a non-cleavable linker, a cleavable linker between the scFv and transferrin protein can reduce exocytosis, enhancing the activity of the scFv.